

# Increasing agility and visibility in scientific publishing

Beatriz D. Schaan<sup>1</sup>

<https://orcid.org/0000-0002-2128-8387>

Bruno Ferraz-de-Souza<sup>2</sup>

<https://orcid.org/0000-0003-4863-2544>

Since its inception, AE&M aimed to establish itself as a leading source of high-quality scientific information in the areas of endocrinology and metabolism (1). In that sense, maintaining open access to our articles was paramount to amplify the reach of such information in a globalized, albeit inequitable, world (2). Aiming to continue to serve the community of readers, authors, and reviewers in the best possible way, two new implementations are underway: AE&M has joined PubMed Central (PMC), and from May 2023, AE&M will adopt the continuous publication model.

AE&M's incorporation into PMC reflects its growth and scientific relevance in the field. PMC is a free full-text repository of biomedical and life sciences journal literature at the U.S. National Institutes of Health's National Library of Medicine (NIH/NLM), directly linked to its preeminent search engine. Created in 2000, it houses more than 7.6 million records and, like SciELO, PMC-indexed journals make their issues and articles available in full format. Its global reach will certainly bring even more visibility and prominence to the research findings published in AE&M.

Another remarkable achievement is the adoption of the continuous publication model, beginning next month. This means that articles will be released online as soon as they are ready for publication, without the need to wait for other articles to compose a complete issue of the journal. This change aims to increase the efficiency of the publication process and to ensure that readers have faster access to important research findings in the areas of endocrinology and metabolism. We also believe that this change will benefit our authors, providing greater visibility and recognition for their work.

With these changes, AE&M aligns itself with recent trends in scientific publishing to increase the agility in making research available for the community. We will keep the high standards of quality that are expected of AE&M, and we hope that these implementations will further enhance the experience for our readers and authors. These achievements result from the effort and commitment of the entire editorial team, to which we are immensely grateful. Our community is responsible for allowing AE&M to progress as a valuable and reputable source of information in our field.

Disclosure: no potential conflict of interest relevant to this article was reported.

## REFERENCES

1. Schaan BD. The continuity of a new era in the AE&M. *Arch Endocrinol Metab.* 2023 Jan 18;67(1):1-2.
2. Bronstein MD. Farewell message from the Editor-in-chief. *Arch Endocrinol Metab.* 2022 Nov 17;66(6):775.

<sup>1</sup> Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brasil. Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brasil  
<sup>2</sup> School of Medicine, University of Notre Dame Australia, Fremantle, Australia

## Correspondence to:

Beatriz D. Schaan  
 Hospital de Clínicas de Porto Alegre  
 Rua Ramiro Barcelos, 2350  
 90035-903 – Porto Alegre, RS, Brasil  
[aem@endocrino.org.br](mailto:aem@endocrino.org.br)

Received on Apr/25/2023  
 Accepted on May/2/2023

DOI: 10.20945/2359-399700000658



This is an open-access article distributed under the terms of the Creative Commons Attribution License